Natera. has been granted a patent for a method that enhances the accuracy of genetic data analysis from limited samples, such as embryonic cells or cancer cell DNA. The technique involves reconstructing incomplete genetic information using data from related individuals and employs next-generation sequencing for analysis. GlobalData’s report on Natera gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Natera, AI-assisted genome sequencing was a key innovation area identified from patents. Natera's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Method for determining genetic data from cancer cell dna
The granted patent US12065703B2 outlines innovative methods for analyzing genetic data from cancer cells using cell-free DNA extracted from biological samples, particularly blood. The primary method involves obtaining cell-free DNA, ligating adapters with universal amplification sequences, and performing targeted amplification through techniques such as targeted PCR and sequencing-by-synthesis. This process allows for the detection of specific genetic alterations, including point mutations, insertions, and deletions, as well as the amplification of single nucleotide polymorphism (SNP) loci. The methods emphasize the importance of generating reliable genetic data, with claims indicating that the confidence in SNP calling can reach up to 99%.
Additionally, the patent describes a systematic approach for preparing a DNA fraction from biological samples, which includes extracting cell-free DNA, amplifying target loci, and analyzing the resulting amplification products. The analysis involves sequencing these products to derive genetic data and determining the most likely genotypes based on allele frequencies. The methods also address potential challenges in genetic data quality, acknowledging issues such as allele drop-out errors and measurement bias, and propose normalization techniques to enhance data accuracy. Overall, the patent presents a comprehensive framework for advancing cancer genomics through improved methodologies for genetic analysis.
To know more about GlobalData’s detailed insights on Natera, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
